Patient Derived Xenograft Market to Expand at a Healthy Growth Rate in the Coming Years

Patient Derived Xenograft/PDX Models and prevention methods basically aim at protecting a person from acquiring an infection from another person via microorganisms such as, virus, bacteria, fungi, etc., especially in hospitals. The market for Patient Derived Xenograft/PDX Models is basically categorized into sterilization and disinfection methods. Owing to the rising aging population and increase in the number of cases of chronic diseases, the market for Patient Derived Xenograft/PDX Models saw a healthy growth in the past few years.

What the Market Looks Like?

Predicted to grow at a CAGR of 16.7% during the forecast period, the global Patient Derived Xenograft market is estimated to reach USD 167.6 Million by 2022. In 2017, North America is estimated to account for the largest share of the global PDX models market, followed by Europe.

On the basis of tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.

Based on application, the PDX models market is further segmented into the preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251&utm_source=OpenPR-16-Dec-2019&utm_medium=PaidPR

What Drives the Market?

The growth of the global market for Patient Derived Xenograft/PDX Models is primarily influenced by the following factors:
• Growing Demand for Personalized Medicine
• Continuous Support for Cancer Research From Public as Well as Private Sector
• Growth in the Number of Pharmaceutical R&D Activities

Geographical growth scenario of Patient Derived Xenograft/PDX Models Market

North America accounted for the largest share of the PDx models market in 2017, followed by Europe. The large share of the North American PDX models market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore.

Request Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251&utm_source=OpenPR-16-Dec-2019&utm_medium=PaidPR

Leading market players and strategies adopted

The prominent players in the Patient Derived Xenograft/PDX Models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.